Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/KDM4C_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/KDM4C_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/KDM4C_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/KDM4C_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/KDM4C_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/KDM4C_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/KDM4C_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004854528 | Skin | AK | response to steroid hormone | 73/1910 | 339/18723 | 4.51e-10 | 5.24e-08 | 73 |
GO:00165709 | Skin | AK | histone modification | 84/1910 | 463/18723 | 1.10e-07 | 4.95e-06 | 84 |
GO:007138326 | Skin | AK | cellular response to steroid hormone stimulus | 46/1910 | 204/18723 | 1.79e-07 | 7.37e-06 | 46 |
GO:003052226 | Skin | AK | intracellular receptor signaling pathway | 55/1910 | 265/18723 | 2.26e-07 | 9.03e-06 | 55 |
GO:000632518 | Skin | AK | chromatin organization | 73/1910 | 409/18723 | 1.40e-06 | 4.26e-05 | 73 |
GO:00063384 | Skin | AK | chromatin remodeling | 51/1910 | 255/18723 | 1.95e-06 | 5.73e-05 | 51 |
GO:003052119 | Skin | AK | androgen receptor signaling pathway | 15/1910 | 44/18723 | 1.66e-05 | 3.16e-04 | 15 |
GO:003051820 | Skin | AK | intracellular steroid hormone receptor signaling pathway | 27/1910 | 116/18723 | 3.24e-05 | 5.47e-04 | 27 |
GO:004340120 | Skin | AK | steroid hormone mediated signaling pathway | 29/1910 | 136/18723 | 9.31e-05 | 1.25e-03 | 29 |
GO:00331439 | Skin | AK | regulation of intracellular steroid hormone receptor signaling pathway | 19/1910 | 74/18723 | 1.17e-04 | 1.48e-03 | 19 |
GO:00607656 | Skin | AK | regulation of androgen receptor signaling pathway | 10/1910 | 28/18723 | 2.78e-04 | 2.94e-03 | 10 |
GO:000975517 | Skin | AK | hormone-mediated signaling pathway | 34/1910 | 190/18723 | 8.18e-04 | 6.80e-03 | 34 |
GO:00064825 | Skin | AK | protein demethylation | 10/1910 | 33/18723 | 1.22e-03 | 9.31e-03 | 10 |
GO:00082145 | Skin | AK | protein dealkylation | 10/1910 | 33/18723 | 1.22e-03 | 9.31e-03 | 10 |
GO:00700764 | Skin | AK | histone lysine demethylation | 9/1910 | 28/18723 | 1.34e-03 | 1.00e-02 | 9 |
GO:00165774 | Skin | AK | histone demethylation | 9/1910 | 31/18723 | 2.95e-03 | 1.87e-02 | 9 |
GO:0030522111 | Skin | SCCIS | intracellular receptor signaling pathway | 26/919 | 265/18723 | 6.33e-04 | 9.33e-03 | 26 |
GO:0048545112 | Skin | SCCIS | response to steroid hormone | 30/919 | 339/18723 | 1.37e-03 | 1.57e-02 | 30 |
GO:001657016 | Skin | SCCIS | histone modification | 37/919 | 463/18723 | 2.53e-03 | 2.44e-02 | 37 |
GO:001657712 | Skin | SCCIS | histone demethylation | 6/919 | 31/18723 | 3.53e-03 | 3.13e-02 | 6 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KDM4C | SNV | Missense_Mutation | rs780836880 | c.362N>A | p.Arg121His | p.R121H | Q9H3R0 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
KDM4C | SNV | Missense_Mutation | rs182255463 | c.676N>G | p.Gln226Glu | p.Q226E | Q9H3R0 | protein_coding | tolerated(0.24) | benign(0.24) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KDM4C | SNV | Missense_Mutation | rs191848178 | c.1888N>T | p.Ala630Ser | p.A630S | Q9H3R0 | protein_coding | deleterious(0.01) | probably_damaging(0.957) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KDM4C | SNV | Missense_Mutation | novel | c.1611N>A | p.Asn537Lys | p.N537K | Q9H3R0 | protein_coding | tolerated(0.2) | benign(0.014) | TCGA-BH-A6R8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KDM4C | SNV | Missense_Mutation | | c.1439N>A | p.Ile480Lys | p.I480K | Q9H3R0 | protein_coding | tolerated(0.95) | benign(0) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KDM4C | SNV | Missense_Mutation | | c.145N>C | p.Val49Leu | p.V49L | Q9H3R0 | protein_coding | deleterious(0) | benign(0.013) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
KDM4C | SNV | Missense_Mutation | rs373633491 | c.1192N>A | p.Ala398Thr | p.A398T | Q9H3R0 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
KDM4C | SNV | Missense_Mutation | | c.1352C>T | p.Ser451Leu | p.S451L | Q9H3R0 | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
KDM4C | insertion | Frame_Shift_Ins | novel | c.1907_1908insCTGGTGCTCTGTAAGATTTTATAAAGTGCTGTTCTTGTGGAGT | p.Thr637TrpfsTer37 | p.T637Wfs*37 | Q9H3R0 | protein_coding | | | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KDM4C | deletion | Frame_Shift_Del | | c.2601delN | p.Asn869ThrfsTer2 | p.N869Tfs*2 | Q9H3R0 | protein_coding | | | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PYROGALLOL RED | PYROGALLOL RED | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Pyrido[1,2-a]indole-1.-carboxylic acid analog 2 | | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Pyrido[1,2-a]indole-1.-carboxylic acid analog 4 | | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PYRIDINE-2,4-DICARBOXYLIC ACID | CHEMBL316034 | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | SKF-38393 | SKF-38393 | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Pyrido[1,2-a]indole-1.-carboxylic acid analog 7 | | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | TYRPHOSTIN 23 | TYRPHOSTIN 23 | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | PMID25468267-Compound-46 | | |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | N-METHOXYCARBONYLMETHYL-OXALAMIC ACID METHYL ESTER | CHEMBL92309 | 19359167 |
23081 | KDM4C | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Pyrido[1,2-a]indole-1.-carboxylic acid analog 1 | | |